Hannover Medical School

FDA approves SciSparc's Phase IIb clinical trials for SCI-110 in treating Tourette Syndrome, following positive Phase IIa results showing tic reduction.

FDA approves SciSparc's SCI-110 Phase IIb clinical trials for Tourette Syndrome, to be conducted at Yale, Hannover, and Tel Aviv Medical Centers.

SciSparc Ltd. submitted an Investigational New Drug application for its phase IIb clinical trial of SCI-110 to treat Tourette Syndrome, to be conducted at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The trial aims to assess SCI-110's efficacy, safety, and tolerability in adult patients using a daily oral treatment, with a focus on tic severity change and adverse events.